Insilico Medicine and SK Biopharmaceuticals have launched a neuroimmune AI drug discovery collaboration that could generate up to $2.5 billion in value. The partnership assigns Insilico’s Pharma.AI platform for target validation, generative chemistry, and molecule optimization, while SK contributes development and clinical capabilities for programs reaching late-stage development and commercialization. The structure reflects a common bifurcated model in AI-enabled R&D: Insilico focuses on early-to-mid discovery delivery, and SK steers later-stage development, regulatory engagement, and commercial execution. The scope targets neuroimmune disorders affecting the central nervous system. For investors and pipeline strategists, the key datapoint is not only the headline valuation range, but also the explicit allocation of SK’s clinical assets to convert AI-discovered candidates into real drug programs, potentially shortening the time from target selection to clinical entry.